Abstract LB-221: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer. A study of the stand up to cancer (SU2C) consortium
Ramanathan R, Barrett M, Weiss G, Posner R, NV R, Jameson G, Demeure M, Hoering A, Stites E, Maitra A, Fulk M, Hidalgo M, Von Hoff D. Abstract LB-221: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer. A study of the stand up to cancer (SU2C) consortium. Cancer Research 2012, 72: lb-221-lb-221. DOI: 10.1158/1538-7445.am2012-lb-221.Peer-Reviewed Original ResearchMetastatic pancreatic cancerPhase II studyMolecular profilingPercutaneous biopsyPerformance statusPancreatic cancerNon-cross-resistant regimenOutcome of salvage therapyPatients treated with FOLFIRIRefractory metastatic pancreatic cancerMetastatic pancreatic cancer patientsSurvival rateTreating metastatic pancreatic cancerAdequate bone marrowAdequate performance statusAneuploid tumour cell populationsYear survival rateAmerican Association for Cancer ResearchEfficacy of therapyFactors of patientsTumor cell populationLong-term survivalInsufficient tumorSalvage therapyStudies of therapy